Mr has made over 1 trades of the Nextcure Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,242 units of NXTC stock worth $11,128 on 8 April 2015.
The largest trade he's ever made was exercising 8,242 units of Nextcure Inc stock on 8 April 2015 worth over $11,128. On average, Mr trades about 211 units every 0 days since 2015. As of 8 April 2015 he still owns at least 23,302 units of Nextcure Inc stock.
You can see the complete history of Mr Richman stock trades at the bottom of the page.
Michael S. Richman MSBA is the Co-Founder, CEO, Pres & Director at Nextcure Inc.
As the Co-Founder, CEO e Pres & Director of Nextcure Inc, the total compensation of Mr MSBA at Nextcure Inc is $726,425. There are 1 executives at Nextcure Inc getting paid more, with Steven Cobourn having the highest compensation of $993,341.
Mr MSBA is 60, he's been the Co-Founder, CEO e Pres & Director of Nextcure Inc since . There are 8 older and 10 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.
Over the last 6 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong e Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Nextcure Inc executives and other stock owners filed with the SEC include: